| (a) | by deleting item (2) of paragraph 1 and substituting the following item: | “(2) | 1‑(4‑Bromo‑2,5‑dimethoxyphenyl)propan‑2‑amine (also known as 4‑Bromo‑2,5‑dimethoxy‑α‑methylphenethylamine, 4‑Bromo‑2,5‑dimethoxyamphetamine, Brolamfetamine or DOB) and its bromo and dimethoxy positional isomers in the phenyl ring”; |
|
|
| (b) | by deleting item (12) of paragraph 1 and substituting the following item:| “(12) | 1‑(2,5‑Dimethoxy‑4‑methylphenyl)propan‑2‑amine (also known as 2,5‑Dimethoxy‑4,α‑dimethylphenethylamine, 2‑Amino‑1-(2,5‑dimethoxy‑4‑methyl)phenylpropane or DOM) and its methyl and dimethoxy positional isomers in the phenyl ring”; |
|
|
| (c) | by deleting item (12A) of paragraph 15 and substituting the following item:| “(12A) | 2‑(Ethylamino)‑1‑phenylhexan‑1-one (also known as N‑Ethylhexedrone or Ethyl‑hexedrone)”; |
|
|
| (d) | by inserting, immediately after item (24) of paragraph 15, the following item:| “(24A) | 1‑Phenyl‑2-(pyrrolidin‑1‑yl)hexan‑1‑one (also known as Alpha‑Pyrrolidinohexiophenone or Alpha‑PHP or α‑PHP)”; |
|
|
| (e) | by inserting, immediately after item (2) of paragraph 17, the following item:| “(2AAA) | 6‑Allyl‑6‑nor‑lysergic acid diethylamide (also known as N‑Allyl‑nor‑LSD or AL‑LAD) and its acyclic secondary and tertiary amide structural isomers”; |
|
|
| (f) | by inserting, immediately after item (2A) of paragraph 17, the following item:| “(2AAB) | N‑(1‑Amino‑3,3‑dimethyl‑1‑oxobutan‑2‑yl)‑1‑butyl-1H‑indazole‑3‑carboxamide (also known as 2‑[(1‑Butyl‑1H‑indazol‑3‑yl)formamido]-3,3‑dimethylbutanamide or ADB‑BUTINACA) and its N‑(1‑amino‑1‑oxohexan‑2‑yl) isomers”; |
|
|
| (g) | by inserting, immediately after item (2CA) of paragraph 17, the following item:| “(2CB) | N‑(1‑Amino‑3,3‑dimethyl‑1‑oxobutan‑2‑yl)‑1‑(4-hydroxybutyl)‑1H‑indazole‑3‑carboxamide and its N‑(1‑amino‑1‑oxohexan‑2‑yl) isomers and their respective hydroxy positional isomers in the butyl group”; |
|
|
| (h) | by deleting item (2G) of paragraph 17 and substituting the following item:| “(2G) | N‑(1‑Amino‑3‑methyl‑1‑oxobutan‑2‑yl)-1-(4-fluorobenzyl)‑1H‑indazole‑3‑carboxamide (also known as N‑[1‑Amino‑3‑methyl‑1‑oxobutan‑2‑yl]-1-[(4‑fluorophenyl)methyl]‑1H‑indazole‑3‑carboxamide or AB‑FUBINACA) and its N‑(1‑amino‑1‑oxopentan‑2‑yl) and N‑(1‑amino‑2‑methyl‑1‑oxobutan‑2‑yl) isomers and their respective fluoro positional isomers in the phenyl ring”; |
|
|
| (i) | by inserting, immediately after item (6G) of paragraph 17, the following items:| “(6H) | 1‑Butanoyl‑N,N‑diethyllysergamide (also known as 1‑Butanoyl‑LSD or 1B‑LSD) and its acyclic secondary and tertiary amide structural isomers | | (6I) | 2‑(1‑Butyl‑1H‑indazole‑3‑carboxamido)‑3,3-dimethylbutanoic acid and its hexanoic acid isomers”; |
|
|
| (j) | by inserting, immediately after item (8A) of paragraph 17, the following item:| “(8AAA) | 1‑(4‑Chloro‑2,5‑dimethoxyphenyl)propan‑2‑amine (also known as 4‑Chloro‑2,5‑dimethoxy‑α‑methylphenethylamine, 4‑Chloro‑2,5‑dimethoxyamphetamine, DOC, 3C‑C, 4‑Cl‑2,5‑DMA or 4‑Chloro‑2,5‑DMA) and its chloro and dimethoxy positional isomers in the phenyl ring”; |
|
|
| (k) | by inserting, immediately after item (14) of paragraph 17, the following item:| “(14A) | 2‑[1‑(4,5‑Dihydroxypentyl)‑1H‑indazole‑3-carboxamido]-3,3‑dimethylbutanoic acid and its hexanoic acid isomers and their respective dihydroxy positional isomers in the pentyl group”; |
|
|
| (l) | by inserting, immediately after item (19AAB) of paragraph 17, the following item:| “(19AAC) | 6‑Ethyl‑6‑nor‑lysergic acid diethylamide (also known as ETH‑LAD) and its acyclic secondary and tertiary amide structural isomers”; |
|
|
| (m) | by inserting, immediately after item (19ABE) of paragraph 17, the following item:| “(19ABF) | 2‑Fluorodeschloroketamine (also known as 2‑Fluoroketamine or 2‑FDCK) and its fluoro positional isomers in the phenyl ring”; |
|
|
| (n) | by inserting, immediately after item (20AA) of paragraph 17, the following item:| “(20AB) | 5‑(5‑Fluoropentyl)‑2‑(2‑phenylpropan‑2‑yl)-pyrido[4,3‑b]indol-1-one (also known as 2‑Cumyl‑5‑(5‑fluoropentyl)‑gamma‑carbolin‑1‑one or 5‑Fluoro‑cumyl‑PEGACLONE) and its phenylpropyl isomers and their respective fluoro positional isomers in the pentyl group”; |
|
|
| (o) | by inserting, immediately after item (27DA) of paragraph 17, the following item:| “(27DB) | Lysergic acid 2,4‑dimethylazetidide (also known as LSZ)”; |
|
|
| (p) | by deleting item (28FA) of paragraph 17 and substituting the following item:| “(28FA) | Methyl 2‑[1‑(4‑fluorobutyl)‑1H‑indazole‑3-carboxamido]‑3,3‑dimethylbutanoate (also known as Methyl 2-{[1‑(4-fluorobutyl)-1H-indazole-3-carbonyl]amino}-3,3‑dimethylbutanoate, 4F‑MDMB‑BINACA, 4F‑MDMB-BUTINACA or 4‑Fluoro‑MDMB-BINACA) and its hexanoate isomers and their respective fluoro positional isomers in the butyl group”; |
|
|
| (q) | by deleting items (28H) and (28I) of paragraph 17 and substituting the following items: | “(28H) | Methyl 2‑[1‑(5‑fluoropentyl)‑1H‑indazole‑3-carboxamido]‑3‑methylbutanoate (also known as Methyl 2‑{[1-(5-fluoropentyl)-1H‑indazole‑3-carbonyl]amino}-3-methylbutanoate, 5F-AMP, 5‑Fluoro‑AMP, 5F-MMB‑PINACA, 5F‑AMB‑PINACA, 5‑Fluoro‑AMB or 5‑Fluoro‑MMB‑PINACA) and its pentanoate isomers and their respective fluoro positional isomers in the pentyl group | | (28I) | Methyl 2‑[1‑(5‑fluoropentyl)‑1H-indole‑3-carboxamido]‑3,3‑dimethylbutanoate (also known as Methyl 2‑{[1-(5-fluoropentyl)‑1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate, 5F‑MDMB‑PICA, 5F‑MDMB‑2201, 5‑Fluoro‑MDMB‑2201 or 5‑Fluoro‑MDMB‑PICA) and its hexanoate isomers and their respective fluoro positional isomers in the pentyl group”; |
|
|
| (r) | by inserting, immediately after item (37) of paragraph 17, the following item:| “(37A) | 2‑[1‑Pent‑4‑en‑1‑yl]‑1H‑indazole‑3‑carboxamido]-3,3‑dimethylbutanoic acid and its hexanoic acid isomers and their respective pentenyl positional isomers in the pentyl group”; |
|
|
| (s) | by inserting, immediately after item (38) of paragraph 17, the following item:| “(38AAA) | 1‑Pentyl‑N‑(2‑phenylpropan‑2‑yl)‑1H‑indole‑3-carboxamide (also known as Cumyl‑PICA) and its phenylpropyl isomers”; and |
|
|
| (t) | by inserting, immediately after item (38AA) of paragraph 17, the following items:| “(38AB) | 5‑{3‑[(2‑Phenylpropan‑2‑yl)carbamoyl]‑1H‑indol‑1-yl}pentanoic acid and its phenylpropyl isomers | | (38AC) | 2-(2‑Phenylpropan‑2‑yl)‑5‑pentyl‑pyrido[4,3‑b]indol-1-one (also known as 2‑Cumyl‑5‑pentylgamma‑carbolin‑1‑one or cumyl‑PEGACLONE or SGT‑151) and its phenylpropyl isomers | | (38AD) | 1‑Propionyl‑N,N‑diethyllysergamide (also known as 1‑Propionyl‑LSD or 1P‑LSD) and its acyclic secondary and tertiary amide structural isomers | | (38AE) | 6‑Propyl‑6‑nor‑lysergic acid diethylamide (also known as PRO‑LAD) and its acyclic secondary and tertiary amide structural isomers”. |
|
|
